Cargando…

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives

SIMPLE SUMMARY: Five years of therapy remains the standard for adjuvant endocrine therapy in early breast cancer. However, the recurrence risk remains elevated beyond this time period. Estimating the risk of recurrence as well as the efficacy of therapy is important in the selection of patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bekes, Inga, Huober, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453164/ https://www.ncbi.nlm.nih.gov/pubmed/37627218 http://dx.doi.org/10.3390/cancers15164190

Ejemplares similares

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
por: Sella, Tal, et al.
Publicado: (2023)

An unmet need: tailoring extended adjuvant endocrine therapy
por: Bianchini, G, et al.
Publicado: (2013)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer
por: Lambert, Leah K., et al.
Publicado: (2021)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis
por: Peleg Hasson, S., et al.
Publicado: (2021)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials()
por: Pala, Laura, et al.
Publicado: (2023)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review
por: Yussof, Izzati, et al.
Publicado: (2022)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
por: Lambert, Leah K., et al.
Publicado: (2018)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy
por: Dell’Acqua, Giorgio, et al.
Publicado: (2020)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Oncologists’ perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer
por: Eraso, Yolanda
Publicado: (2019)

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
por: Güth, U, et al.
Publicado: (2008)

Causal Attributions in Breast Cancer Patients Planning to Undergo Adjuvant Endocrine Therapy
por: Park, Seul Ki, et al.
Publicado: (2021)

Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies
por: Shawky, Michael S., et al.
Publicado: (2016)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
por: Bartlett, J M S, et al.
Publicado: (2019)

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010)

Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
por: Lee, Joo Yun, et al.
Publicado: (2018)

Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials
por: Xie, Ming, et al.
Publicado: (2022)

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis
por: Yu, Zhu, et al.
Publicado: (2017)

Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia
por: Saiful Bahri, Athirah, et al.
Publicado: (2021)

Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Women’s Decision Making in an Online Breast Cancer Forum
por: Eraso, Yolanda, et al.
Publicado: (2021)

An emerging generation of endocrine therapies in breast cancer: a clinical perspective
por: Patel, Rima, et al.
Publicado: (2023)

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review
por: Toivonen, Kirsti I., et al.
Publicado: (2020)

Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
por: Li, Li, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ukhtm7b5opr86ertmk1uhu2iji